Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Non Operating Income (2020 - 2025)

Arcutis Biotherapeutics has reported Non Operating Income over the past 6 years, most recently at -$6.4 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$6.4 million for Q4 2025, up 52.13% from a year ago — trailing twelve months through Dec 2025 was $443000.0 (up 842.55% YoY), and the annual figure for FY2025 was $443000.0, up 842.55%.
  • Non Operating Income for Q4 2025 was -$6.4 million at Arcutis Biotherapeutics, down from $2.0 million in the prior quarter.
  • Over the last five years, Non Operating Income for ARQT hit a ceiling of $5.2 million in Q2 2024 and a floor of -$13.4 million in Q4 2024.
  • Median Non Operating Income over the past 5 years was $2.0 million (2022), compared with a mean of $184400.0.
  • Peak annual rise in Non Operating Income hit 8400.0% in 2022, while the deepest fall reached 2293.06% in 2022.
  • Arcutis Biotherapeutics' Non Operating Income stood at -$40000.0 in 2021, then surged by 8400.0% to $3.3 million in 2022, then crashed by 396.54% to -$9.8 million in 2023, then crashed by 36.19% to -$13.4 million in 2024, then skyrocketed by 52.13% to -$6.4 million in 2025.
  • The last three reported values for Non Operating Income were -$6.4 million (Q4 2025), $2.0 million (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.